Recent Updates
Recently added Catalysts
LIVN Positive Sentiment

LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: LivaNova PLC reported third-quarter revenue of $393.1 million, a 9.9% increase from the prior year. The company raised its full-year 2026 revenue and adjusted diluted EPS guidance. This reflects strong operational performance and positive financial momentum for the medical technology firm.

Market Sentiment Analysis

POSITIVE FACTORS

  • Third-quarter revenue increased by 9.9%.
  • Adjusted diluted EPS guidance raised for full-year 2026.
  • Strong performance in constant-currency terms.

Full Press Release Details

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $393.1 million increased 9.9% on a reported basis and 10.0% on a constant-currency basis as compared to the prior-year period Third-quarter U.S. GAAP diluted earnings per share of $0.11 and adjusted diluted earnings per

Frequently Asked Questions

What was LivaNova's Q3 2026 revenue?

LivaNova reported a Q3 2026 revenue of $393.1 million.

How much did revenue increase in Q3 2026?

Revenue increased by 9.9% compared to the prior-year period.

What guidance did LivaNova raise?

LivaNova raised its full-year 2026 revenue and adjusted diluted EPS guidance.

What was the adjusted diluted EPS for Q3 2026?

The adjusted diluted EPS for Q3 2026 was $0.11.

ShareAdd on Google
Tags: LIVN LivaNova Q3 2026 revenue guidance earnings
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$517M liquidity · $0M/mo burn
Low dilution risk
Lead asset
REPLY 200Phase 3
Bradycardia →